Sept 20 (Reuters) – Allergan Inc on Tuesday said it
had paid $50 million for Akarna Therapeutics Ltd, a privately
held company developing treatments for a incurable fatty liver
disease called NASH.
The post Allergan buys second fatty liver-disease company appeared first on NASDAQ.